Breast cancer (BC) has several distinct molecular subtypes, including estrogen receptor (ESR1) positive andtriple negative BC (TNBC). A significant proportion of ESR1-positive therapy sensitive-BCs (TS-BC) initiallyrespond to antiestrogens or aromatase inhibitors, but become therapy resistant-BCs (TR-BC) and progress toincurable metastases. Further, TNBC subtype has a more aggressive clinical course and lack targetedtherapies. Development of effective therapies for women with TR-BC and TNBCs represents the highest unmetneed.
A Collaboration of the San Antonio Bioscience and Medical Research Community
A first-of-its-kind initiative between public and private sector to catalog and highlight Bioscience research in the city of San Antonio and the surrounding areas.
Latest Projects
The University of Texas at San Antonio
The University of Texas at San Antonio
The University of Texas at San Antonio
The University of Texas at San Antonio
The University of Texas at San Antonio
The University of Texas at San Antonio